Since the frequency of <i>BAP1</i> mutations in ccRCC patients was approximately 10%-20%, as reported previously, we also tried to explore the potential mechanisms benefitting from the nilapanib. Here, BAP1 is linked to nonpapillary renal cell carcinoma.